Fuan Pharmaceutical Co., Ltd. obtained the clinical approval for the treatment of hypertension with lekadipine hydrochloride

According to the information on CFDA website, Fuan Pharmaceutical (300194 SZ) has completed the examination and approval of lekadipine hydrochloride and its preparation for hypertension People from the company told the media that lecardine hydrochloride obtained clinical approval and it is expected that the product will be on the market for a long time "I haven't got the approval yet." According to the public information, lekadipine hydrochloride is a new generation of dihydropyridine calcium channel blocker with multiple effects, which is used to treat mild and moderate essential hypertension Compared with similar drugs, it has the characteristics of strong efficacy, long acting time and high blood vessel selectivity At present, only Chongqing shenghuaxi Pharmaceutical Co., Ltd is a manufacturer in China Fu'an pharmaceutical industry is one of the major domestic antibiotic manufacturers Its operating revenue and profit largely depend on its main product, aztreonam In order to alleviate the adverse effects of the anti drug restriction policy, the company has actively transformed its specialty drugs in recent years At present, the company has more than 30 specialty drugs reviewed by CFDA.